Literature DB >> 12180296

[Treatment of chronic hepatitis C in special groups].

Marc Bourlière1, Philippe Halfon, Isabelle Portal.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12180296

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


× No keyword cloud information.
  5 in total

1.  Full-length genome sequences of five hepatitis C virus isolates representing subtypes 3g, 3h, 3i and 3k, and a unique genotype 3 variant.

Authors:  Ling Lu; Chunhua Li; Jie Yuan; Teng Lu; Hiroaki Okamoto; Donald G Murphy
Journal:  J Gen Virol       Date:  2012-11-14       Impact factor: 3.891

2.  Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006.

Authors:  Francois Roman; Karin Hawotte; Daniel Struck; Anne-Marie Ternes; Jean-Yves Servais; Vic Arendt; Patrick Hoffman; Robert Hemmer; Therese Staub; Carole Seguin-Devaux; Jean-Claude Schmit
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

3.  Efficacy of interferon alpha-2b with or without ribavirin in thalassemia major patients with chronic hepatitis C virus infection: A randomized, double blind, controlled, parallel group trial.

Authors:  Hamid Kalantari; Neda Rad
Journal:  J Res Med Sci       Date:  2010-11       Impact factor: 1.852

4.  The Prevalence of Hepatitis B and C Among Prisoners in Kahramanmaras, Turkey.

Authors:  Derya Keten; Mehmet Emin Ova; Hamit Sirri Keten; Alper Keten; Evrim Gulderen; Seray Tumer; Ahmet Caliskan; Suleyman Kulotu
Journal:  Jundishapur J Microbiol       Date:  2016-02-13       Impact factor: 0.747

Review 5.  Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials.

Authors:  Ehsan Aminizadeh; Seyed Moayyed Alavian; Ali Akbari Sari; Nasser Ebrahimi Daryani; Bita Behnava
Journal:  Hepat Mon       Date:  2016-03-06       Impact factor: 0.660

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.